Switzerland's Cannabis Pilot Programs

Background: Swiss drug policy before the pilots

Switzerland's modern drug policy rests on the so-called four-pillar model—prevention, therapy, harm reduction, and repression—adopted in the 1990s in response to the open drug scenes in Zurich's Platzspitz and Letten parks. That framework produced internationally studied heroin-assisted treatment programs and a pragmatic stance toward managing problem drug use.

Cannabis, however, remained illegal under the Federal Act on Narcotics (Betäubungsmittelgesetz, BetmG). A 2008 referendum to legalize cannabis was rejected by approximately 63% of voters ^[1]. A 2013 amendment decriminalized possession of up to 10 grams, replacing criminal proceedings with a 100-franc fine for adults ^[2]. Starting in 2016, low-THC 'CBD cannabis' (under 1.0% THC) became legally sold as a tobacco substitute and grew into a sizable industry; high-THC cannabis remained prohibited.

Article 8a: The legal pathway to pilot trials

In September 2020, the Swiss parliament passed an amendment to the Narcotics Act adding Article 8a, the so-called 'experimental article' (Experimentierartikel) ^[3]. It entered into force on May 15, 2021 Strong evidence ^[3]. The article authorizes time-limited, scientifically evaluated pilot trials for the controlled distribution of cannabis to adults who already use it Strong evidence ^[3].

The accompanying Ordinance on Pilot Trials with Cannabis (Verordnung über Pilotversuche nach dem Betäubungsmittelgesetz, BetmPV), effective March 31, 2021, set out the conditions ^[4]:

• Pilots run a maximum of five years, extendable by two.
• Participants must be adults already consuming cannabis and resident in the pilot's canton.
• Cannabis must be Swiss-grown, organic where feasible, with declared THC and CBD content and standardized packaging.
• Sales are non-profit-oriented, with prices roughly matching the illicit market.
• Cantonal ethics committees must approve each study; the Federal Office of Public Health (FOPH/BAG) authorizes and supervises.
• Each pilot must publish a scientific evaluation.

This legal framework addressed proposals blocked under the unamended law—Bern, Basel, Geneva, and Zurich had sought pilot authorization starting in 2017 but were rejected by the FOPH ^[4].

Timeline of the pilots (2023–2026)

January 30, 2023 — Weed Care (Basel). Switzerland's first sanctioned adult-use cannabis sale in modern history Strong evidence. Run by the University of Basel's Psychiatric Clinics in collaboration with the city of Basel, Weed Care enrolled approximately 370 participants who buy cannabis at nine designated pharmacies. Products include flower and hashish at multiple THC concentrations.

September 2023 — Züri Can (Zurich). The largest pilot, authorized for up to 2,100 participants distributed across pharmacies, social clubs, and the city-run Drogeninformationszentrum. Led by the city of Zurich in partnership with the University of Zurich.

2023–2024 — Additional pilots. Bern (SCRIPT, led by Addiction Switzerland and the University of Bern), Lausanne (Cann-L), Geneva, and Biel/Bienne launched with varying designs: pharmacy-based, cannabis-social-club style, or hybrid models.

As of mid-2026, several thousand participants are enrolled across Switzerland. Each study collects data on consumption patterns, mental and physical health, substance use disorder symptoms, and interaction with the illicit market. Early interim reports from Weed Care described participants' baseline demographics and enrollment characteristics, though full peer-reviewed outcome data from any pilot is not yet published Weak / limited.

How the pilots operate

Pilots are strictly controlled research environments, not a free market. A typical participant journey follows this path:

1. Enrollment: Prove adult residency in the host canton, document prior cannabis use, and sign informed consent at the study site.
2. Study ID: Receive a card; all purchases are logged.
3. Purchase: Buy from approved outlets (pharmacies in Basel, a mix of clubs and pharmacies in Zurich, etc.).
4. Labeling: Products carry labels with THC%, CBD%, batch number, and harm-reduction information ^[4].
5. Compliance: Complete periodic questionnaires; some studies include clinical assessments. Monthly purchase caps exist (commonly 10 g of THC equivalent) ^[4].

Participants must comply with existing law: public consumption is prohibited, driving remains subject to the zero-tolerance THC traffic law, and resale results in exclusion ^[4]. Producers must be licensed Swiss cultivators; several CBD-industry growers pivoted to supply the trials.

Common myths and accurate framing

Myth: 'Switzerland legalized weed in 2023.' False. Recreational cannabis remains illegal under the Narcotics Act outside the pilots Strong evidence ^[3]. Only enrolled participants in authorized studies can legally buy regulated high-THC cannabis Strong evidence.

Myth: 'Anyone can join a pilot if they visit Switzerland.' False. Pilots are restricted to adult residents of the host canton with documented prior cannabis use Strong evidence ^[4]. Tourists are not eligible.

Myth: 'The pilots will automatically lead to legalization.' Uncertain. The pilots are designed to inform a future policy debate. A parliamentary sub-commission has drafted a regulated-market proposal in parallel, but any nationwide legalization would still require new legislation and likely a public referendum Disputed ^[5].

Myth: 'The Swiss model is identical to the Dutch coffeeshop model.' No. Dutch coffeeshops are decades-old tolerated retail with no formal scientific evaluation framework. The Swiss pilots are time-limited research projects with ethics oversight, mandatory prospective data collection, and a defined sunset date Strong evidence.

Historical significance and research context

Switzerland's pilots occupy a distinctive position in global cannabis policy history. Uruguay legalized recreational cannabis outright in 2013 without a controlled comparison phase Strong evidence. Canada legalized in 2018, also without prospective research design Strong evidence. U.S. state markets evolved through ballot initiatives with minimal systematic research planning. By contrast, the Swiss trials were designed in advance by researchers as prospective studies with defined outcome measures, ethics oversight, and mandatory data collection before the intervention began Strong evidence.

This approach is not unprecedented in drug policy research—heroin-assisted treatment and supervised consumption sites have been rigorously studied—but applying it to regulated adult-use cannabis distribution at scale is novel. Whether the resulting evidence from the late 2020s will actually shape Swiss law, or serve as a model for other countries, remains an open question. Final reports from the longest-running pilots are not expected until the late 2020s.

Sources

How this page was made

Related

• Cannabis Possession Limits in Switzerland — What Swiss law actually says about carrying cannabis, the 10-gram rule, and how pilot prog...
• Cannabis Social Equity Programs in Switzerland — Switzerland's pilot trials are public-health studies, not social equity or restorative-jus...
• Cannabis Tax Structures in Switzerland — Switzerland taxes cannabis in three separate buckets: CBD as tobacco substitute, medical b...
• UN Drug Treaties and Cannabis — Three UN treaties control cannabis globally; legalization exists despite treaty language f...